Fig. 1: Combination of tautomycin and enzalutamide synergistically inhibited prostate cancer cell viability. | Cell Death Discovery

Fig. 1: Combination of tautomycin and enzalutamide synergistically inhibited prostate cancer cell viability.

From: Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer

Fig. 1

A, B The cell viability of LNCaP (A) and C4-2 (B) were measured using MTT assay after being treated with indicated drugs and 1 nM DHT for 48 h. C, D The synergist effect of tautomycin and enzalutamide was calculated with the Chou-Talalay method as described previously. The LNCaP (C) and C4-2 (D) cells were treated with a gradient dose of tautomycin and enzalutamide individually or in combination, and the cell viability was detected using MTT assay after 48 h. Represented images of EdU incorporation in LNCaP (E) and C4-2 (F) cells treated with tautomycin and enzalutamide in the presence of 1 nM DHT. Nuclei were stained with Hoechst 33342 (scale bars: 50 μm). G, H Represented images of colony formation assay in LNCaP (G) and C4-2 (H) cells. #Synergy by bliss-independent analysis.

Back to article page